A systematic review of digital technology to evaluate motor function and disease progression in motor neuron disease

Emily Beswick1,2,3 · Thomas Fawcett4 · Zack Hassan1,2,3 · Deborah Forbes1,2,3 · Rachel Dakin1,2,3 · Judith Newton1,2,3 · Sharon Abrahams3,5 · Alan Carson1 · Siddharthan Chandran1,2,3,6 · David Perry1,2 · Suvankar Pal1,2,3

Received: 21 March 2022 / Revised: 22 July 2022 / Accepted: 25 July 2022 / Published online: 9 August 2022 © The Author(s) 2022

Abstract
Amyotrophic lateral sclerosis (ALS) is the most common subtype of motor neuron disease (MND). The current gold-standard measure of progression is the ALS Functional Rating Scale—Revised (ALS-FRS(R)), a clinician-administered questionnaire providing a composite score on physical functioning. Technology offers a potential alternative for assessing motor progression in both a clinical and research capacity that is more sensitive to detecting smaller changes in function. We reviewed studies evaluating the utility and suitability of these devices to evaluate motor function and disease progression in people with MND (pwMND). We systematically searched Google Scholar, PubMed and EMBASE applying no language or date restrictions. We extracted information on devices used and additional assessments undertaken. Twenty studies, involving 1275 (median 28 and ranging 6–584) pwMND, were included. Sensor type included accelerometers (n = 9), activity monitors (n = 4), smartphone apps (n = 4), gait (n = 3), kinetic sensors (n = 3), electrical impedance myography (n = 1) and dynamometers (n = 2). Seventeen (85%) of studies used the ALS-FRS(R) to evaluate concurrent validity. Participant feedback on device utility was generally positive, where evaluated in 25% of studies. All studies showed initial feasibility, warranting larger longitudinal studies to compare device sensitivity and validity beyond ALS-FRS(R). Risk of bias in the included studies was high, with a large amount of information to determine study quality unclear. Measurement of motor pathology and progression using technology is an emerging, and promising, area of MND research. Further well-powered longitudinal validation studies are needed.

Keywords Amyotrophic lateral sclerosis · Motor neuron disease · Devices · Sensors · Clinical trials

Introduction
Amyotrophic lateral sclerosis (ALS) is the most common subtype of motor neuron disease (MND), a neurodegenerative condition characterised by progressive loss of motor function. Only 51.3% of people with MND (pwMND) survive more than 12 months from diagnosis [1]. The only globally licensed disease-modifying treatment for MND, riluzole, has limited efficacy and extends survival by just 2–3 months [2]. There is an urgent clinical need for more effective therapies and many clinical trials are in progress or planned [3]. Accurate measurement of symptom progression in MND is a significant challenge in both clinical and research settings.

The current gold standard for evaluating physical symptom severity and disease progression is the Amyotrophic Lateral Sclerosis Functional Rating Scale—Revised...
Increasing participant burden [5]. Frequent assessments points and longer duration follow-up, in function, necessitating large trial sample sizes, more item scores that may not be sensitive to smaller changes in function, necessitating large trial sample sizes, more frequent assessments points and longer duration follow-up, increasing participant burden [5].

Remote monitoring of function may also improve clinical care delivery [6]. Collecting information between appointments may facilitate delivery of more personalised care [6, 7]. The prognostic capacity of devices is an area of active investigation in a range of neurological conditions [8]. Improved ability to predict disease trajectory and early identification of impairment may also help with care planning.

MND is characterised by clinical heterogeneity in site of onset and disease progression [9]. The different types of devices available offer the opportunity to evaluate different body regions, whilst enabling each person to act as their own baseline for detecting change and progression [10].

The potential of greater sensitivity for detecting change with these devices and their implementation as alternative outcome measures may lead to significant reduction in sample size requirements for trials by 30.3% and 44.6% for 18-months trials [10]. Smaller sample size requirements for detecting effects of new medicines reduces trial delivery costs and shortens timelines for trials [10].

Using devices for remote data collection also reduces the need for frequent trial appointments for participants. Decentralised trial delivery offers the opportunity for more frequent assessments, potentially further reducing sample size requirements, for example weekly versus monthly ALS-FRS(R) completion [11, 12]. The opportunity for remote data collection also offers trialists the opportunity to reduce the burden of trial participation on people with MND and optimise retention [13].

Activity monitors evaluate changes in participants’ overall capability for engaging in physical activity [11], whilst wearable devices containing an inertial measurement unit (IMU) enable researchers to provide a picture of an individual’s ability to move their limbs [10]. An IMU is contained within a wearable device and used to measure velocity, orientation and gravitational force, which in turn can provide detailed information on the participant’s movements. Within the IMU are an accelerometer, gyroscope and magnetometer sensor. Accelerometers measure acceleration from inertia (movement from a resting baseline), gyroscope measure angular rotation (direction of movement) with the magnetometer improving the accuracy of the gyroscope’s determination of direction [14].

Smartphones are also used to collate passive (automatically collected by the phone itself) and active (entered by participants into specialised apps or web forms) data on function, symptoms and daily activity [13]. Electrical impedance myography devices apply a low-intensity electrical current to a limb, to evaluate an area of muscle and through repeated measurements, we can evaluate changes in the structure and composition of the muscle as it degrades due to disease progression, offering a potential alternative biomarker for people with MND [15]. Dynamometry is also focussed on the muscles, evaluating decline through measuring strength of pressure muscles are capable of, this can be focussed on a specific area of the body (eg hand function and grip strength) or more global decline [16].

In other progressive motor disorders, such as Parkinson’s disease, devices have offered an alternative method of continuous and objective monitoring of motor symptoms in both clinical care and trial delivery [17]. The clinical utility of these devices and their potential suitability as trial outcome measures, in people with MND has steadily gained attention in research. In this study, we will explore the current landscape of research in this area: the devices used, aspects of MND evaluated and directions for future work.

**Aim**

The aims of this study are to improve understanding of the types of device currently used in research to evaluate motor symptoms in pwMND, and to explore if studies consider the acceptability of devices to participants, and the feasibility their use for routine data collection in MND.

**Objectives**

The objective of this study is to systematically review previous studies reporting use of devices in people with MND and their suitability to evaluate motor progression in research and clinical care for pwMND.

**Hypothesis**

We hypothesise that the majority of studies in this area will be exploratory: utilising small sample sizes and shorter lengths of follow-up but encouraging for future exploration in research. In addition, we hypothesise that studies primarily focus on comparing devices to performance on the ALS-FRS(R) questionnaire. We hypothesise that pwMND will find these devices to be acceptable to use.
Methods

Search strategy

We completed a systematic and unbiased literature search on the 13th June 2022, adhering to PRISMA guidelines for conducting and reporting systematic reviews, attached in Appendix 1_PRISMA Guidelines. We searched EMBASE with the terms “amyotrophic lateral sclerosis” OR “motor neuron(e) disease” AND “devices” with the headings expanded to include all relevant sub-headings for devices. We also searched PubMed using (amyotrophic lateral sclerosis [MeSH Terms]) OR (motor neuron disease [MeSH Terms]) AND (devices [MeSH Terms]). In addition, we searched Google Scholar with the search terms “amyotrophic lateral sclerosis” OR “motor neurone disease” AND “wearable devices”, as “devices” alone provided an unmanageable number of results on this database.

Outside of the United Kingdom MND is primarily referred to by its most common subtype, amyotrophic lateral sclerosis (ALS), as a result both terms were included. No language or date restrictions were applied. Reference lists of returned search results were also screened for additional suitable articles.

Screening for eligibility

Results were screened for suitability by two independent reviewers, with any disputes resolved by a third reviewer. Full details of inclusion and exclusion criteria used are provided in Table 1 and the number of results included at each stage in the screening process is outlined in Fig. 1.

Data extraction

Two reviewers extracted information from each search result on the devices used and study participant characteristics. We also noted any additional assessments used to evaluate the devices’ suitability and evaluation of participant feedback on the suitability of these devices.

Risk of bias

Two authors (EB, TF) independently assessed the methodological quality of all included studies using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool for quality assessment questionnaire [19]. Studies were judged to either have high or low risk of bias for each domain based on composite assessment of 13 questions. All studies fitting inclusion criteria were included in the review despite their risk for bias.

Results

An overview of the studies including the specific devices and comparative assessment tools used for concurrent validity is summarised in Table 2 with the full dataset available in Appendix 2_Project Data.

1827 search results were identified of which 20 were studies eligible for inclusion (see PRISMA diagram in Fig. 1 for more details).

These 20 studies included 2044 participants (a mean of 102, range 6–584), 1275 (62%) of whom had MND. The remaining individuals were included as healthy controls or as people with other neurological conditions to offer comparison groups. 17 studies (85%) recorded participants’ ALS-FRS(R) scores [20], to evaluate concurrent validity of the devices [12, 13, 16, 21–33].

Length of follow-up and number of assessment points varied greatly across the studies, from a single time-point of assessment [25] to study duration of 36 months [28]. The median length of follow-up was 6 months, with a mean of 8 months. The number of assessment points, and different tools used, are summarised in Table 2. Devices

Table 1 Inclusion and exclusion criteria

| Inclusion criteria | Exclusion criteria |
|--------------------|-------------------|
| • Cohort study, case–control study, feasibility study, letter, case series or case report AND; | • Not including any participants with any form of motor neuron disease |
| • Study population includes people with motor neuron disease or (including any of the listed subtypes: amyotrophic lateral sclerosis, progressive muscular atrophy, primary lateral sclerosis or progressive bulbar palsy) AND; | • Paediatric or non-human study population |
| • The device measures an aspect of motor system pathophysiology (such as movement, strength or impedance) OR; | • Review articles, conference abstracts, book chapter, poster or clinical trial |
| • The device output is used to assess progression of physical symptoms OR; | • Electronic medical device is invasive or implanted |
| • Gait analysis when focussed on progression or evaluation of declining function | • Device measures speech, respiratory function, energy expenditure, cognitive function or an aspect of disease unrelated to motor pathophysiology |
| | • Sensor output used for rehabilitative or assistive purposes (e.g. user–computer interface, communication aid and prosthetic) |
| | • Gait analysis focussed on identifying pathological gait, or differential diagnosis between neurological conditions |
were used as a part of larger study protocols, such as the Ontario Neurodegenerative Research Initiative (ONDRI), to differentiate presentation and progression across different neurological conditions [28, 34, 35].

Two studies reported on the feasibility of a fully remote research delivery model [12, 30]. Recruitment and informed consent were successfully completed using the internet and electronic transfer of medical records to confirm eligibility. Remote data collection was a more complex issue. Some participants struggled to set up study platforms independently, with up to 28% of participants with MND unable to record a first measurement [30] and only 15% of participants retained to the 9-months time-point (Table 2).

Five of the studies explored a form of participant experience on the suitability of the devices to people with MND. Participants completed questionnaires, reported adverse effects and rated the burden of using devices. In one study, semi-structured interviews were undertaken to provide participants with the opportunity to discuss their experiences [36]. Concerns ranged from the fairly innocuous, limited clothing options and worry of losing regarding the ActiGraph [10], to more serious adverse effects of skin and subcutaneous tissue disorders in 6 of 25 participants, resulting in 2 participants withdrawing from the study [26].
| Lead author          | Total number of participants | Number of participants with MND | Information on disease subtype | Length of follow-up | Frequency of data collection | Function assessed                              | Motor sensor                                      | Additional assessments | Comparison devices | Data on participant experience reported? | Company providing device | Cost of device |
|---------------------|------------------------------|--------------------------------|--------------------------------|---------------------|-----------------------------|-----------------------------------------------|--------------------------------------------------|-----------------------|------------------|--------------------------------------|---------------------------|---------------|
| Andres (2017) [16]  | 100                          | 100                            | No subtype data                | 15 months           | Every 5 months              | • Upper and lower limb strength               | • Accurate Test of Limb Isometric Strength (ATLIS) | None                  | No                | No data                              | ATLIS                      | No data        |
| Bakers (2021) [21] | 88                           | 45                             | 91% ALS 7% PMA 2% PLS         | Single time-point   | Not applicable              | • Upper and lower limb strength               | • Portable fixed dynamometer                   | • ALS-FRS(R)          | Hand held dynamometer               | No                        | Not applicable | No data        |
| Berry (2019) [13]  | 23                           | 22                             | No subtype data                | 6 months            | Every 3 months              | • Speech • Cognition • General functioning (self-reported ALS-FRS(R), communication and movement logs) | • Smartphone (Beiwe app)                       | • ALS-FRS(R)          | ALS-CBS                  | No                        | Onnela Lab at Harvard University | No data        |
| Beukenhorst (2021) [22] | 8                             | 8                              | No subtype data                | 3 months            | 2-month-long time periods   | • General activity calculated from location data | • Smartphone (Beiwe app)                       | • ALS-FRS(R)          | None                       | No                        | Onnela Lab at Harvard University | No data        |
| Die Bie (2017) [23] | 10                           | 10                             | No subtype data                | 12 months           | Approximately every 3 months | • Upper limb function                         | • Reachable workspace (Microsoft Kinect)         | • ALS-FRS(R)          | Forced vital capacity (Puritan Bennett Renaissance II Spirometer) | No                        | Microsoft       | $41           |
| Esser (2011) [37]   | 72                           | 7                              | No subtype data                | Single time-point   | Not applicable              | • Lower limb                                 | • Inertial measurement unit                   | • Gait                 | Walking speed and distance          | No                        | MTx Xsens        | No data        |
| Lead author                  | Total number of participants | Number of participants with MND | Information on disease subtype | Length of follow-up | Frequency of data collection | Function assessed                      | Motor sensor                        | Additional assessments | Comparison devices | Data on participant experience reported? | Company providing device | Cost of device |
|-----------------------------|------------------------------|--------------------------------|--------------------------------|---------------------|-----------------------------|---------------------------------------|-------------------------------|---------------------|------------------|----------------------------------------|--------------------------|----------------|
| Garcia-Gancedo (2021) [24]  | 25                           | 25                             | No subtype data               | 12 months           | Every 3 months              | • Upper limb function                | Accelerometer (MegaFaros)     | • ALS-FRS(R) | • Heart rate variability (Mega Fast Fix electrode patch) | Yes                      | Mega Electronics | $595  |
| Geronimo (2021) [25]        | 30                           | 30                             | 84% ALS 14% PLS 2% PMA        | Single time-point   | Not applicable               | • Lower limb                         | Accelerometers                  | • Gait               | None             | No MetaMotionR                          | MetaMotionR              | $78            |
| Godkin (2021) [36]          | 39                           | 5                              | No subtype data               | 7 days              | Daily                       | • Upper and lower limb function      | Accelerometer                  | • Temperature | None             | Yes (De-brief interviews to discuss experience) | ActivInsights GENEActiv Originals Bittium Faros | $226  |
| Kelly (2020) [26]           | 25                           | 25                             | No subtype data               | 12 months           | Wear device 3 days a month  | • Activity                           | Accelerometer (Mega Faros 180) | • ALS-FRS(R) | • Speech (digital data capture)          | No                       | Mega Electronics | $596  |
| Londral (2013) [27]         | 6                            | 3                              | No subtype data               | 6 months            | Every 3 months              | • Upper limb function (typing ability) | Accelerometer (BioSignals PLUX) | None               | None             | No BioSignals Plux                      | BioSignals Plux          | $95            |
| Londral (2016) [38]         | 45                           | 19                             | No subtype data               | 2–20 months         | Every 4–6 months depending on progression | • Upper limb function (fine motor typing) | Accelerometer                  | ALS-FRS(R) | None             | No data                                | No data                  | No data         |
| Lead author           | Total number of participants | Number of participants with MND | Information on disease subtype | Length of follow-up | Frequency of data collection | Function assessed                                                                 | Motor sensor assessments                                                                 | Additional assessments | Comparison devices | Data on participant experience reported? | Company providing device | Cost of device |
|----------------------|------------------------------|-------------------------------|-------------------------------|---------------------|-----------------------------|----------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|-----------------------|------------------|----------------------------------------|------------------------|---------------|
| Montero-Odasso       | 500                          | 40                            | No subtype data               | 36 months           | Annually                    | Lower limb function, Balance, Dual tasking (motor and cognitive tasks)          | Gait (GAITRite® mat or PKMas electronic walkway), Accelerometer (GENEActiv)               | None                  | No               | GAIT Rite                                            | $28,500                 |               |
| (2017) [28]          |                              |                               |                               |                     |                             |                                                                                  |                                                                                          |                       |                  |                                        |                       |               |
| Oskarsson            | 27                           | 10                            | No subtype data               | Single time-point   | Not applicable              | Upper limb function                                                         | Reachable workspace (Microsoft Kinect)                                                   | ALS-FRS(R)            | No               | Microsoft                                            | $41                    |               |
| (2016) [29]          |                              |                               |                               |                     |                             |                                                                                  |                                                                                          |                       |                  |                                        |                       |               |
| Rutkove              | 141                          | 111                           | No subtype data               | 9 months            | Daily data collection for 90 days, bi-weekly for 180 days ALS-FRS(R) weekly | Activity, Activity and sleep tracker (Mi Band), Smartphone app (ALS AT HOME) | ALS-FRS(R)                                                                            | Spirometer (AirSmart), Electrical impedance myography (Skulpt Scanner) Speech (ALS AT HOME) | Yes (REDCap survey on patient-reported experience) | Xiaomi                     | $29                   |               |
| (2019) [30]          |                              |                               |                               |                     |                             |                                                                                  |                                                                                          |                       |                  |                                        |                       |               |
| Lead author         | Total number of participants | Number of participants with MND | Information on disease subtype | Length of follow-up | Frequency of data collection | Function assessed                  | Motor sensor                        | Additional assessments | Comparison devices | Data on participant experience reported? | Company providing device | Cost of device |
|---------------------|-------------------------------|--------------------------------|--------------------------------|---------------------|------------------------------|-----------------------------------|-------------------------------------|-----------------------|-------------------|----------------------------------------|--------------------------|---------------|
| Rutkove (2020) [12] | 113                           | 113                            | No subtype data               | 9 months            | Daily for 3 months, twice weekly for 6 months ALS-FRS(R) weekly | Activity • Upper limb • Respiratory function • Speech | Activity tracker (Mi Band) | ALS-FRS(R) • Patient-reported outcome measures | Hand grip (Camry Handgrip Dynamometer) • Slow-vital capacity (Air Smart) • Electrical impedance myography (Skulpt Scanner) • Speech (ALS at Home app) | Yes (participant-reported survey on experience) | Xiaomi         | $29                       |
| Schefner (2018) [31]| 106                           | 46                             | No subtype data               | 8 months            | Every 2 months              | Detect changes in muscle structure | Myolex mView                     | None                  | NDD EasyO-oneVR Plus Diagnostic Spirometer MicroFet2VR hand-held dynamometer | No                       | Myolex        | No data                   |
| Trevizan (2018) [32]| 60                            | 30                             | No subtype data               | Single time-point   | Not applicable              | Evaluate finger motion           | Microsoft Kinect • Leap Motion Control • Touch-screen laptop | ALS-FRS(R)            | None              | No Microsoft Ultraleap             | $41                      | $247          |
Devices used

Accelerometers were used in nine studies [10, 25–28, 33, 36–38] including those using an accelerometer and additional sensors (gyroscope and magnetometer) in an inertial measurement unit. These sensors were used to evaluate spatio-temporal parameters of gait specifically in three studies [25, 28, 37]. Five studies evaluated lower limb function using accelerometers worn on the waist or ankle during walking tasks [25, 28, 33, 36, 37]; two of which also involved wearing one the wrist to assess upper limb functioning [33, 36]. In addition, two studies used small accelerometers on participants’ fingers to evaluate fine motor skills through measuring typing speed, strength and accuracy [27, 38].

The Microsoft Kinect sensor uses a single camera system to evaluate depth and an individual’s motion, that can be used to capture reachable workspace [39], a clinically relevant measure of upper limb function, providing information on capacity to move the arms and reach within their environment. The Microsoft Kinect sensors were used to evaluate upper limb function, through mapping reachable workspace, in three studies [23, 29, 32]. One study explored the suitability of non-immersive virtual reality tasks as a method of assessing upper limb functionality and cognition, comparing touchscreen laptops, Microsoft Kinect motion sensor and finger motion sensor system Leap Motion Control® [32].

Smartphone applications, such as the Beiwe [13, 22] and ALS AT HOME apps were used [12], offering frequent remote data collection, often using a wide range of endpoints. Smartphone data were categorised as active (directly inputted by participants) and passive (using existing smartphone data such as GPS and call logs), used to calculate activity [13, 22]. Participant-completed ALS-FRS was supplemented with additional questionnaires, motor tests, digital spirometry and cognitive testing.

Six studies evaluated ‘activity monitors’ that collect, and present, data on measurements such as time spent active, sleeping and metabolic equivalent task (MET). MET is a calculation based on body weight to estimate the number of calories burned during an activity or ‘task’ [40]. Monitoring of general activity using wearable devices in studies also enabled researchers to collect data outside of the artificial clinic environment of changes in the participants’ daily functioning, with minimal burden on participants. The Mi Band [12], ActiGraph [10] and Mega Faros sensor [26] were used to evaluate real-world activity levels and heart rate variability during rest and exercise. Activity monitors were combined with additional devices to evaluate respiratory function, such as the AirSmart spirometer [30], and upper limb function, using the Camry digital handgrip dynamometer [12].
Some studies focussed on devices that specifically aimed to evaluate progression in muscle strength. Electrical impedance myography, which works through the application of low-intensity electrical currents to the muscles, was shown to be potentially suitable to evaluate MND progression [31]. Two studies explored the use of fixed and portable dynamometry devices to assess global and precise muscle strength [16, 21], with hand-held dynamometry devices a common comparison measure to establish the suitability of new exploratory devices [12, 31].

### Data analysis

Accelerometer devices collect raw data in three axes from the primary accelerometer sensor. The raw data are analysed using either data visualisation tools and pre-existing algorithms provided by the vendors or devising new data analysis models [26]. Working with the raw data to generate novel scoring thresholds enables investigators to replicate findings in the future studies, compare participants and provide preliminary validity data on the prognostic probability of the devices used.

The data from activity monitors and accelerometers are used to correlate the level of change expected based on standardised tests of disease progression and functionality; in MND studies, this is primarily the ALS-FRS(R). Other studies use raw data from the devices to quantify the individual’s movements when performing a standardised clinical measurement or motor function assessments such as the 6-minute walking test [28], arm raising [29] or typing [27]. Assessments that may be clinically relevant to people with MND may not yet have reliability data on which devices are suitable to evaluate motor functionality.

### Table 3 Types of devices used

| Type of device            | Areas of functioning evaluated                          | Brand examples in included studies | Studies using |
|---------------------------|--------------------------------------------------------|-----------------------------------|---------------|
| Activity monitor          | • Heart rate                                           | Mega Fast Fix heartbeat sensor    | [24]          |
|                           | • Personal activity                                    | Mi Band                           | [12, 30]      |
|                           | • Breathing function                                   | Mega Faros Sensor                 | [26]          |
|                           | • Stress                                               |                                   |               |
|                           | • Sleep                                                |                                   |               |
|                           | • Step count                                           |                                   |               |
| Accelerometer             | • Activity periods                                     | Actigraph                         | [10, 33]      |
|                           | • Wear time                                            | BioSignals Plus                   | [27]          |
|                           | • Metabolic rate                                       | Mega Faros 180                    | [26]          |
|                           | • Energy expenditure                                   | MetaMotionR                       | [25]          |
|                           | • Steps taken                                          | MTXsens                           | [37]          |
|                           |                                                        | GENEActiv Originals               | [28, 36]      |
|                           |                                                        | Bittium Faros                     | [36]          |
| Smartphone app            | • Behavioural patterns                                 | Beiwe                             | [13, 22]      |
|                           | • Sleep data                                           | ALS AT HOME                       | [12, 30]      |
|                           | • Social interactions                                  |                                   |               |
|                           | • Physical mobility                                    |                                   |               |
|                           | • Gross motor activity                                 |                                   |               |
|                           | • Cognitive functioning                                |                                   |               |
|                           | • Speech production                                    |                                   |               |
| Gait                      | • Functional walking                                   | MetaMotionR                       | [25]          |
|                           | • Temporal and spatial parameters of movement          | GAIT Rite                         | [28]          |
|                           |                                                        | MTXsens                           | [37]          |
| Movement sensor           | • Reachable workspace for upper limbs                  | Microsoft Kinect                  | [23, 29, 32]  |
|                           | • Fine motor skill on touch screen devices             | Leap Motion Control               | [32]          |
| Spirometer                | • Vital capacity                                       | EasyOne                           | [13]          |
|                           |                                                        | AirSmart                          | [12, 30]      |
|                           |                                                        | Puritan Bennett Renaissance II    | [23]          |
| Electrical impedance myography | • Biomarker of neuromuscular health                  | Skulpt Scanner                    | [12, 30]      |
|                           |                                                        | Myolex mView                      | [31]          |
| Computerised microphone   | • Speech capture                                       | Not specified                      | [24, 26, 33]  |
| Dynamometry               | • Limb and grip strength                               | Accurate test of limb isometric strength (ATLIS) | [16, 21] |
|                           |                                                        | Portable fixed dynamometer (PFD)   | [12, 30]      |
|                           |                                                        | Camry handgrip dynamometer        |               |

Devices may have multiple functionalities and not all functionalities will be automatically enabled.
during them, a key foundation in considering the suitability of a device to this population.

**Risk of bias in included studies**

Risk of bias in the included studies is shown in Appendix 3 QUADAS Data. No study fulfilled all QUADAS-2 criteria for low risk of bias. 31% (126/408) responses were deemed “Unclear” as the information regarding sample decisions, reference and index tests used were not available in the study report meaning the conclusions regarding risk of bias were affected by lack of data availability. However, for all the studies, there was low concern that the index test used, the interpretation of the index test or the participants included, differed from the review question.

**Discussion**

Digital devices have provided an alternative to traditional questionnaire-based assessment methods to detect progression in clinical trials [41] and research studies [42] in a range of neurological disorders. These devices offer a potential new direction in MND research and clinical care and this review explores the current landscape in this area; the device types used and the suitability and acceptability for pwMND.

**Establishing suitability of devices**

Studies in this review reported that device outcome measures correlated with the ALS-FRS(R), suggesting that devices have concurrent validity with traditional measures of disease progression [12, 13, 16, 21–33].

Accelerometer endpoints (average daytime active, percentage of daytime active, total daytime activity score and total 24-h activity score) showed moderate to strong correlations with ALS-FRS(R) scores over a period of 48 weeks [26]. Strong associations between accelerometer endpoints and ALS-FRS(R) scores for up to 21 months and accelerometer data indicated less variability over time [10].

Worsening total ALS-FRS(R) scores, and declining ALS-FRS(R) upper limb sub-scores, were associated with reduced reachable workspace evaluated through Kinect sensors [29]. De Bie et al. [23] also demonstrated the potential utility of device outcome measures, as in their study Kinect sensors were able to detect change in upper limb function when the ALS-FRS(R) did not indicate any significant change over a 1-year period. Scores from activity monitors, specifically the amount of time spent active, correlated with global and motor-specific scores on the ALS-FRS(R), suggesting the potential utility of these devices to evaluate function with low burden to participants [25].

Devices also offered the opportunity to take ALS-FRS(R) data collection out of the clinic, with self-reported ALS-FRS(R) scores correlating highly with clinic-based assessments [13], working towards establishing app-based evaluation and fully remote studies [30] as a potentially suitable alternative to burdensome clinic appointments for people with MND involved in research.

However, the sensitivity of the ALS-FRS(R) to detect smaller changes in functioning is limited [5]. When establishing the suitability of devices for people with MND, concurrent validity with existing measures is a helpful starting point, but should not be the only consideration for a devices’ utility in research and clinical evaluation. Responsiveness to change in other physical markers of progression, such as respiratory function and muscle strength, may also be relevant.

**Responsiveness to change over time**

Only three studies explored the devices at a single time-point [25, 29, 37]. The remaining studies (n = 17) explored change in motor symptoms over time, between 2-week and 36-month study duration.

As when evaluating any progressive disorder, establishing the suitability of these devices to detect change was crucial. Devices were often compared to established measures of disease progression, to establish the ability to detect expected decline and ultimately detect potential treatment effects as biomarkers in clinical trials [31].

The broad range of aspects of functioning which can be evaluated using devices is particularly useful in a condition such as MND with heterogeneous presentation and progression. Devices offer objective measures of both global and precise decline and have been shown by studies in this review to successfully differentiate disease progression [10] and discriminate between neurological conditions [37].

Increasing the length of follow-up, and the number of measurements, to evaluate the reliability of a device across repeated measurements will be a key avenue for future work.

**Establishing acceptability of devices**

Current data on the acceptability of devices to people with MND were limited, with only five (36%) studies reporting data on participant experience [10, 12, 24, 30, 36]. For the studies that did report on participant experience, feedback was generally positive with participants reporting low burden, an improved sense of control over their condition and minimal impact on their day-to-day activities [10, 12].

The logistical challenge of remote data collection, potential risk to participant safety, and shift in onus on the participant to collect the data, must be carefully managed by clinical and trial teams. Feedback from participants, rates of adverse events and attrition must be closely explored when
evaluating the suitability of a potential device for use in this population.

**Remote data collection**

A key benefit of wearable devices and other health technologies to evaluate disease progression in MND is their portability and suitability for remote data collection. A recruitment, consent and data collection process that was either fully or partially remote would significantly reduce the burden placed on individuals who wish to participate in clinical trials. It would also minimise burden of repeated travel in this vulnerable group, thereby minimising attrition.

Remote data collection using devices presents unique challenges associated with managing and reducing missing data. Studies involving remote data collection reported missing data due to insufficient device charge and participant adherence to protocol of wearing devices. Inability to use the devices and begin data collection may also be problematic, with one study reporting 13% of healthy controls and 28% of pwMND were unable to obtain a first measurement using the technology provided. Only 15% of participants were retained to the 9-month time-point. With only 15% of participants remaining at the 9-month time-point, our ability to draw conclusions from remotely collected data in these studies is limited [12].

**Participant-led data collection**

The shift to participant-led data collection may be contingent on individuals having a degree of technical knowledge and confidence in their ability to use devices, potentially affecting those who opt to engage [11, 12]. This may bias samples in studies using health technology, for example towards younger individuals, with greater digital literacy and those less affected by upper limb weakness. Clinicians and researchers may pre-emptively address this concern by reducing skills required for people to participate, providing adequate instructions for use, and ongoing technical support.

The use of cloud-based data collection methods may also reduce the onus on participants, enabling remote monitoring of adherence and data management from devices.

The inclusion of devices in study design may result in greater participant burden ranging from the intrusion of remembering to wear sensors to attending more remote appointments. It is important that these factors are considered in study design. This burden may also be felt by caregiving relatives and friends as people with MND experiencing motor decline or cognitive impairment may require prompting and physical assistance from a caregiver to adhere to study requirements.

**Choice of device**

The aim of this study was to systematically review the current landscape of research using devices to explore motor progression in MND. Device suitability is dependent upon the research aims, the intended participant group and project resources but more research into the properties of these devices, and their acceptability to people with MND can help inform future decisions.

A key aspect requiring consideration is the current lack of consensus regarding choices of device for digital data capture. This lack of consensus, linked to the small sample sizes [27] and low quality of existing evidence [29, 37], introduces uncertainty, and may limit uptake in clinical trial design and also patient care.

Prospective studies, with larger sample sizes, longer follow-up durations and direct feedback from device users [43] are required to evaluate the utility of devices and establish which devices are most suitable in MND. The development of strategic guidelines would be beneficial to harmonise approaches and inform future study design and clinical care integration. Many devices contain multiple sensors and investigators must balance the benefits of additional data collection with concerns over decrease battery life and greater data storage requirements. If using accompanying software, the type available for data analysis and data visualisation is relevant in informing design decisions.

**Data analysis and management**

A further potential challenge for researchers incorporating devices in trial design, and clinicians integrating devices into care, is how to use device data to evaluate progression. A clear, pre-defined plan for evaluating digitally derived data, correlating with existing validated outcomes and determining thresholds of progression are crucial [44].

As with any outcome measures, the findings from studies using devices can be affected by missing data. Data points may be compromised due to technical issues of erroneous recordings, transferring and storage of data. Studies included in this review reported issues with missing data affecting the ability to draw clinical conclusions from results, due to participants withdrawing early due to adverse effects [24] or being unable to use the technology to collect data [30]. Investigators must manage the risk of missing data, and develop study-specific plans to account for this in data analysis for future studies.

If investigators intend to use raw data for analysis, how the data is stored and organised and the availability of groups with expertise in this type of data analysis must be a crucial consideration. Concerns regarding data security and adherence to privacy regulations may also be a barrier to integrating technologies in study design. Providing detailed data
management plans, reviewed by specialists in data security will help to pre-emptively address concerns of prospective participants, regulatory bodies and funders.

Cost of devices

A potential concern for prospective users, regulatory bodies, funders, clinicians and research teams is the cost of providing technologies. Accessibility of these devices may be limited by the cost of providing equipment such as tablets and computers, or purchasing specialist voice recognition or eye gaze software. Approximate costs for devices, where available, are reported in Table 2. Resource is also required for storage and interpretation of data requiring interdisciplinary collaboration with clinicians, data scientists, information governance, and IT security. Ensuring future work is not limited in scope by access to devices, will be difficult to address without additional funding for MND care and research.

Conclusion

Overall, the use of devices for measuring disease progression in MND is a promising direction of research. The reviewed literature was primarily proof-of-concept, exploratory studies with shorter periods of follow-up and smaller sample sizes, limiting the conclusions that can be drawn from the findings. In addition, a large amount of data were unavailable to determine risk of bias accurately, and for the information available, a high risk of bias was indicated. The COVID-19 pandemic has highlighted the importance of implementing remote assessment, using the types of technology discussed in this study, for people with MND [45]. Devices offer the opportunity to decentralise trial delivery and reduce the burden felt by participants previously required to travel to additional appointments.

Future work

Clinicians and trialists designing research to incorporate these devices will face a unique set of considerations and challenges. The body region to be assessed, ease of use, frequency and sensitivity of sampling, reliability, cost to purchase, battery life and storage capacity of devices must be evaluated. The shift towards telemedicine in clinical care may offer valuable insights into delivering effecting remote research opportunities for people with MND [46].

This study indicates a variety of devices are potentially suitable to measure physical symptoms in MND and potentially useful as additional outcome measures in trials. The multi-systemic impact of MND presents multiple potential targets for evaluation as potential technological biomarkers, including speech, motor function, cognition and overall functional ability [47].

As there are a number of potentially suitable devices, the decision on what to use must also consider acceptability to participants, cost, area of function to assess and sensitivity to change. Identifying relevant devices, establishing their suitability and providing clear procedures for integration into health research, specifically for MND, are outlined by Van Eijk et al., who highlight the importance of digital biomarkers [44].

When establishing the responsiveness of a device, future research should evaluate progression of each currently affected area of the body, not just as covariance with total scores from existing measures of progression such as the ALS-FRS(R), which may not be sensitive to detect smaller changes in function. Future work should focus on developing guidelines for clinicians and researchers on available devices, suitability for MND and aspects of functioning measured.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00415-022-11312-7.

Author contributions SP and EB contributed to the conception of the project. EB, TF, and SP carried out the literature searches and data acquisition, interpretation and analysis. EB, TF, SP, DF, RD, JN, SA, SC and DP drafted the manuscript. The manuscript was reviewed and approved for publication by all the authors.

Funding The Euan MacDonald Centre for Motor Neuron Disease Research, SC is supported by the UK Dementia Research Institute (DRI), which receives its funding from UK DRI Ltd, funded by the MRC, Alzheimer’s Society and Alzheimer’s Research UK.

Availability of data and materials Appendix 2_Project Data.

Code availability Not applicable.

Declarations

Conflicts of interest Professor Carson is a paid editor at Journal of Neurology, Neurosurgery and Psychiatry, and gives independent testimony in Court on a range of neuropsychiatric topics.

Ethical standard statement The authors confirm that this article complies with ethical standards.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. Leighton DJ et al (2019) Changing epidemiology of motor neuron disease in Scotland. J Neurol 266(4):817–825
2. Miller RG, Mitchell JD, Moore DH (2012) Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD001447.pub3
3. Wong C et al (2021) Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective. Brain Commun 3(4):fcab242
4. Rooney J et al (2017) What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 88(5):381–385
5. van Eijk RP et al (2021) An old friend who has overstayed their welcome: the ALSFRS-R total score as primary endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener 22(3–4):300–307
6. Hobson EV et al (2018) The TiM system: developing a novel telehealth service to improve access to specialist care in motor neurone disease using user-centered design. Amyotroph Lateral Scler Frontotemporal Degener 19(5–6):351–361
7. Hobson EV et al (2016) Using technology to improve access to specialist care in amyotrophic lateral sclerosis: a systematic review. Amyotroph Lateral Scler Frontotemporal Degener 17(5–6):313–324
8. Cohen AB, Nahed BV, Sheth KN (2013) Mobile medical applications in neurology. Neurology 3(1):52–60
9. Beghi E et al (2011) The epidemiology and treatment of ALS: focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotroph Lateral Scler 12(1):1–10
10. van Eijk RPA et al (2019) Accelerometer for remote monitoring of physical activity in amyotrophic lateral sclerosis: a longitudinal cohort study. J Neurol 266(10):2387–2395
11. Rutkove S et al (2020) Accelerating clinical therapeutic trials in ALS through frequent at-home data collection. Neurology 94(15):4921
12. Rutkove SB et al (2020) Improved ALS clinical trials through frequent at-home self-assessment: a proof of concept study. Ann Clin Transl Neurol 7(7):1148–1157
13. Berry JD et al (2019) Design and results of a smartphone-based digital phenotyping study to quantify ALS progression. Ann Clin Transl Neurol 6(5):873–881
14. Ahmad N et al (2013) Reviews on various inertial measurement unit (IMU) sensor applications. Int J Signal Process Syst Transl Neurol 6(5):439–445
15. Andres PL et al (2017) Fixed dynamometry is more sensitive than vital capacity or ALS rating scale. Muscle Nerve 56(4):710–715
16. Ossig C et al (2016) Wearable sensor-based objective assessment of motor symptoms in Parkinson’s disease. J Neural Transm (Vienna) 123(1):57–64
17. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. PLoS Med 6(7):e1000097. https://doi.org/10.1371/journal.pmed1000097
18. Whiting PF et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155(8):529–536
19. Cedarsbaum JM et al (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 169(1–2):13–21
20. Bakers JN et al (2021) Portable fixed dynamometry: towards remote muscle strength measurements in patients with motor neuron disease. J Neurol 268(5):1738–1746
21. Beukenshorst AL et al (2021) Smartphone data during the COVID-19 pandemic can quantify behavioral changes in people with ALS. Muscle Nerve 63(2):258–262
22. de Bie E et al (2017) Longitudinal evaluation of upper extremity reachable workspace in ALS by Kinect sensor. Amyotroph Lateral Scler Frontotemporal Degener 18(1–2):17–23
23. Garcia-Gancedo L et al (2019) Objectively monitoring amyotrophic lateral sclerosis patient symptoms during clinical trials with sensors: observational study. JMIR Mhealth Uhealth 7(12):e13433
24. Geronimo A, Martin AE, Simmons Z (2021) Inertial sensing of step kinematics in ambulatory patients with ALS and related motor neuron diseases. J Med Eng Technol 45(6):486–493
25. Kelly M et al (2020) The use of biotelemetry to explore disease progression markers in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 21(7–8):563–573
26. Londral A et al (2013) A method to detect keystrokes using accelerometry to quantify typing rate and monitor neurodegenerative progression. In NEUROTECHNIX
27. Montero-Odasso M et al (2017) Motor phenotype in neurodegenerative disorders: gait and balance platform study design protocol for the Ontario neurodegenerative research initiative (ONDRI). J Alzheimers Dis 59(2):707–721
28. Oskarsson B et al (2016) Upper extremity 3-dimensional reachable workspace assessment in amyotrophic lateral sclerosis by Kinect sensor. Muscle Nerve 53(2):234–241
29. Rutkove SB et al (2019) ALS longitudinal studies with frequent data collection at home: study design and baseline data. Amyotroph Lateral Scler Frontotemporal Degener 20(1–2):61–67
30. Shefner JM et al (2018) Reducing sample size requirements for future ALS clinical trials with a dedicated electrical impedance myography system. Amyotroph Lateral Scler Frontotemporal Degener 19(7–8):555–561
31. Trevizan IL et al (2018) Efficacy of different interaction devices using non-immersive virtual tasks in individuals with Amyotrophic Lateral Sclerosis: a cross-sectional randomized trial. BMC Neurol 18(1):1–10
32. Vieira FG et al (2022) A machine-learning based objective measure for ALS disease severity. NPJ Digit Med 5(1):1–9
33. Farhan SMK et al (2017) The Ontario neurodegenerative disease research initiative (ONDRI). Can J Neurol Sci 44(2):196–202
34. Vert A et al (2022) Detecting accelerometer non-wear periods using change in acceleration combined with rate-of-change in temperature. BMC Med Res Methodol 22(1):147–147
35. Godkin FE et al (2022) Feasibility of a continuous, multi-sensor remote health monitoring approach in persons living with neurodegenerative disorders: gait and balance platform study design. Gait Posture 34(4):558–560
36. Londral A, Pinto S, de Carvalho M (2016) Markers for upper limb dysfunction in Amyotrophic Lateral Sclerosis using analysis of typing activity. Clin Neurophysiol 127(1):925–931
37. Kuriro G et al (2013) Evaluation of upper extremity reachable workspace using Kinect camera. Technol Health Care 21(6):641–656
38. Canosa A et al (2020) Lifetime sport practice and brain metabolism in Amyotrophic Lateral Sclerosis. NeuroImage 27:102312
disease. A randomized controlled trial. Ann Phys Rehabil Med 62(5):303–312
42. Gijbels D et al (2010) Predicting habitual walking performance in multiple sclerosis: relevance of capacity and self-report measures. Mult Scler J 16(5):618–626
43. van Eijk RP et al (2019) Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. Neurology 92(5):e451–e460
44. van Eijk RPA et al (2021) A road map for remote digital health technology for motor neuron disease. J Med Internet Res 23(9):e28766
45. Bombaci A et al (2021) Telemedicine for management of patients with amyotrophic lateral sclerosis through COVID-19 tail. Neurol Sci 42(1):9–13
46. Pugliese R et al (2022) Emerging technologies for management of patients with amyotrophic lateral sclerosis: from telehealth to assistive robotics and neural interfaces. J Neurol 269(6):2910–2921
47. Ramanarayanan V et al (2022) Speech as a biomarker: opportunities, interpretability, and challenges. Perspect ASHA Special Interest Groups 7(1):276–283